Ophthotech (OPHT) Is At $2.66 Formed Wedge; Profile of 4 Analysts Covering Ironwood Pharmaceuticals, Inc. (IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Logo

Among 15 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 4 have Buy rating, 2 Sell and 9 Hold. Therefore 27% are positive. Ironwood Pharmaceuticals had 38 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Tuesday, May 10 by Mizuho. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Buy” rating by Mizuho on Friday, October 6. The firm earned “Buy” rating on Monday, October 10 by Mizuho. The firm earned “Buy” rating on Thursday, July 20 by Cowen & Co. On Friday, February 19 the stock rating was maintained by Wedbush with “Neutral”. The company was initiated on Friday, December 11 by BTIG Research. The rating was maintained by Cowen & Co with “Buy” on Friday, August 4. Mizuho maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Monday, March 12 with “Hold” rating. The firm has “Sell” rating given on Friday, January 5 by Bank of America. The firm has “Hold” rating given on Friday, July 21 by J.P. Morgan. See Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) latest ratings:

12/03/2018 Broker: Mizuho Rating: Hold New Target: $16.0 Maintain
09/01/2018 Broker: Mizuho Rating: Hold New Target: $16.0 Maintain
05/01/2018 Broker: Bank of America Rating: Sell New Target: $15.0 Downgrade
06/12/2017 Broker: Mizuho Old Rating: Buy New Rating: Neutral Downgrade
04/12/2017 Broker: BTIG Research Rating: Buy New Target: $21.0
04/12/2017 Broker: Morgan Stanley Rating: Hold
27/11/2017 Broker: Credit Suisse Rating: Outperform New Target: $19 Initiates Coverage On
01/11/2017 Broker: Cowen & Co Rating: Buy New Target: $20.0 Maintain

Ophthotech Corporation (OPHT) formed wedge down with $2.47 target or 7.00% below today’s $2.66 share price. Ophthotech Corporation (OPHT) has $96.34 million valuation. The stock decreased 0.56% or $0.02 during the last trading session, reaching $2.66. About 3,798 shares traded. Ophthotech Corporation (NASDAQ:OPHT) has declined 26.03% since April 18, 2017 and is downtrending. It has underperformed by 37.58% the S&P500.

Since December 29, 2017, it had 0 insider purchases, and 9 sales for $126,644 activity. 8,089 shares were sold by SBLENDORIO GLENN, worth $25,804 on Friday, December 29. WOOD BARBARA A sold $2,249 worth of Ophthotech Corporation (NASDAQ:OPHT) on Tuesday, January 2. GUYER DAVID R sold $11,392 worth of stock or 3,516 shares. $1,153 worth of stock was sold by Westby Keith on Tuesday, January 2.

Investors sentiment increased to 0.96 in Q4 2017. Its up 0.26, from 0.7 in 2017Q3. It is positive, as 9 investors sold Ophthotech Corporation shares while 19 reduced holdings. 13 funds opened positions while 14 raised stakes. 18.24 million shares or 0.33% more from 18.17 million shares in 2017Q3 were reported. Federated Invsts Pa accumulated 0% or 55,353 shares. Art Limited Liability Company owns 0.02% invested in Ophthotech Corporation (NASDAQ:OPHT) for 164,177 shares. Royal Bancorp Of Canada owns 1,897 shares. Dekabank Deutsche Girozentrale holds 0% or 26,400 shares. Endurance Wealth has 1,500 shares for 0% of their portfolio. Citadel Advsrs Ltd Liability Co reported 27,956 shares stake. Jacobs Levy Equity Management Inc stated it has 0.03% of its portfolio in Ophthotech Corporation (NASDAQ:OPHT). Meeder Asset Mngmt Inc owns 2,134 shares or 0% of their US portfolio. Cetera Advisor Ntwk Lc has 11,286 shares for 0% of their portfolio. 43,600 are held by California Employees Retirement Sys. New Jersey-based Highlander Ltd Llc has invested 0.01% in Ophthotech Corporation (NASDAQ:OPHT). Barclays Public Lc owns 28,407 shares. Creative Planning invested 0% in Ophthotech Corporation (NASDAQ:OPHT). State Street Corporation stated it has 0% in Ophthotech Corporation (NASDAQ:OPHT). Jpmorgan Chase & Company accumulated 201,762 shares.

Among 13 analysts covering Ophthotech Corporation (NASDAQ:OPHT), 2 have Buy rating, 2 Sell and 9 Hold. Therefore 15% are positive. Ophthotech Corporation has $200 highest and $300 lowest target. $66.78’s average target is 2410.53% above currents $2.66 stock price. Ophthotech Corporation had 29 analyst reports since August 4, 2015 according to SRatingsIntel. The company was maintained on Thursday, August 6 by Stifel Nicolaus. Oppenheimer reinitiated Ophthotech Corporation (NASDAQ:OPHT) on Friday, August 14 with “Outperform” rating. Barclays Capital initiated the stock with “Overweight” rating in Wednesday, April 27 report. The rating was maintained by Chardan Capital Markets with “Buy” on Tuesday, August 4. The company was downgraded on Monday, December 12 by Cowen & Co. The firm has “Mkt Perform” rating given on Monday, December 12 by Leerink Swann. The stock of Ophthotech Corporation (NASDAQ:OPHT) has “Neutral” rating given on Wednesday, February 28 by Chardan Capital Markets. As per Tuesday, December 13, the company rating was upgraded by Goldman Sachs. The rating was maintained by Chardan Capital Markets with “Hold” on Wednesday, July 26. As per Thursday, June 2, the company rating was upgraded by JP Morgan.

Since January 24, 2018, it had 0 insider purchases, and 7 insider sales for $1.22 million activity. Shares for $23,954 were sold by Currie Mark G. The insider Gilbert Halley E sold $113,483. Shares for $52,688 were sold by Consylman Gina. McHugh Julie sold 1,500 shares worth $21,090. The insider OLANOFF LAWRENCE S sold $28,100. MCCOURT Thomas A sold $49,008 worth of stock or 3,343 shares.

The stock increased 0.28% or $0.05 during the last trading session, reaching $17.69. About 37,555 shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has declined 11.53% since April 18, 2017 and is downtrending. It has underperformed by 23.08% the S&P500.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart